ZYME
Zymeworks Inc.
Price Chart
Latest Quote
$23.17
Current Price| Previous Close | $22.53 |
| Open | $22.45 |
| Day High | $23.34 |
| Day Low | $22.45 |
| Volume | 427,551 |
Stock Information
| Shares Outstanding | 74.84M |
| Total Debt | $18.90M |
| Cash Equivalents | $251.93M |
| Revenue | $134.48M |
| Net Income | $-63.43M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.76B |
| EPS (TTM) | $-0.85 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 19/42| Debt to Equity | 0.05 |
| Debt to Earnings | -0.16 |
| Current Ratio | 3.40 |
| Quick Ratio | 3.19 |
| Avg Revenue Growth | 46.50% |
| Profit Margin | -160.80% |
| Return on Equity | -36.22% |
| Avg FCF Growth | -11.26% |
| FCF Yield | -6.41% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $23.17 | 427,551 |
| 2026-01-30 | $22.53 | 560,200 |
| 2026-01-29 | $22.38 | 625,300 |
| 2026-01-28 | $22.31 | 652,800 |
| 2026-01-27 | $23.25 | 472,400 |
| 2026-01-26 | $22.91 | 1,017,600 |
| 2026-01-23 | $23.24 | 742,200 |
| 2026-01-22 | $23.55 | 590,400 |
| 2026-01-21 | $23.95 | 640,200 |
| 2026-01-20 | $23.67 | 645,000 |
| 2026-01-16 | $23.47 | 525,800 |
| 2026-01-15 | $23.63 | 1,130,000 |
| 2026-01-14 | $24.62 | 981,100 |
| 2026-01-13 | $23.92 | 947,000 |
| 2026-01-12 | $23.16 | 1,062,200 |
| 2026-01-09 | $23.17 | 984,100 |
| 2026-01-08 | $23.10 | 1,321,900 |
| 2026-01-07 | $24.85 | 2,527,800 |
| 2026-01-06 | $24.18 | 1,744,700 |
| 2026-01-05 | $25.48 | 1,656,600 |
About Zymeworks Inc.
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
📰 Latest News
A Look At Zymeworks (ZYME) Valuation After Recent Share Price Pullback
Simply Wall St. • 2026-01-29T02:18:49Z
3 Stocks Estimated To Trade At Discounts Of Up To 49.7%
Simply Wall St. • 2025-12-19T11:38:00Z
Is Zymeworks Inc. (NASDAQ:ZYME) Trading At A 50% Discount?
Simply Wall St. • 2025-12-19T10:55:22Z
Oracle initiated, Uber upgraded: Wall Street's top analyst calls
The Fly • 2025-12-03T14:35:07Z
Zymeworks (ZYME): Assessing Valuation After 60% Rally and Recent Earnings Momentum
Simply Wall St. • 2025-11-19T14:14:45Z
JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
Zacks • 2025-11-18T17:16:00Z
Zymeworks to change course, pursue ‘royalty-driven’ biotech model
BioPharma Dive • 2025-11-18T08:38:05Z
Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer
Investor's Business Daily • 2025-11-17T21:44:34Z
Stocks to Watch Recap: Alphabet, Tesla, Netflix, Zymeworks
The Wall Street Journal • 2025-11-17T21:13:22Z
Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.
Barrons.com • 2025-11-17T16:08:00Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $76,304,000 | $76,012,000 | $412,482,000 | $26,680,000 |
| Operating Revenue | $76,304,000 | $76,012,000 | $412,482,000 | $26,680,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $196,121,000 | $214,019,000 | $281,996,000 | $242,352,000 |
| Other Income Expense | $-16,729,000 | $-894,000 | $1,110,000 | $1,309,000 |
| Other Non Operating Income Expenses | $-218,000 | $291,000 | $-42,000 | $118,000 |
| Net Non Operating Interest Income Expense | $19,941,000 | $19,705,000 | $3,596,000 | $1,965,000 |
| Operating Expense | $196,121,000 | $214,019,000 | $281,996,000 | $242,352,000 |
| General And Administrative Expense | $61,500,000 | $70,400,000 | $73,400,000 | $42,600,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-122,695,000 | $-118,674,000 | $124,341,000 | $-211,843,000 |
| Net Interest Income | $19,941,000 | $19,705,000 | $3,596,000 | $1,965,000 |
| Interest Income | $19,941,000 | $19,705,000 | $3,596,000 | $1,965,000 |
| Normalized Income | $-109,651,310 | $-117,494,645 | $123,281,793 | $-213,031,106 |
| Net Income From Continuing And Discontinued Operation | $-122,695,000 | $-118,674,000 | $124,341,000 | $-211,843,000 |
| Total Operating Income As Reported | $-137,110,000 | $-138,053,000 | $130,528,000 | $-215,633,000 |
| Average Dilution Earnings | $140,000 | $0 | $-231,000 | $-28,534,000 |
| Net Income Common Stockholders | $-122,695,000 | $-118,674,000 | $124,341,000 | $-211,843,000 |
| Net Income | $-122,695,000 | $-118,674,000 | $124,341,000 | $-211,843,000 |
| Net Income Including Noncontrolling Interests | $-122,695,000 | $-118,674,000 | $124,341,000 | $-211,843,000 |
| Net Income Continuous Operations | $-122,695,000 | $-118,674,000 | $124,341,000 | $-211,843,000 |
| Pretax Income | $-116,611,000 | $-119,242,000 | $135,234,000 | $-212,359,000 |
| Special Income Charges | $-17,287,000 | $0 | $0 | - |
| Interest Income Non Operating | $19,941,000 | $19,705,000 | $3,596,000 | $1,965,000 |
| Operating Income | $-119,817,000 | $-138,007,000 | $130,486,000 | $-215,672,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-1.62 | $-1.72 | $1.90 | $-4.61 |
| Basic EPS | $-1.62 | $-1.72 | $1.91 | $-4.11 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-3,467,310 | $-5,645 | $92,793 | $2,894 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-92,113,000 | $-119,517,000 | $141,338,000 | $-207,280,000 |
| Total Unusual Items | $-16,511,000 | $-1,185,000 | $1,152,000 | $1,191,000 |
| Total Unusual Items Excluding Goodwill | $-16,511,000 | $-1,185,000 | $1,152,000 | $1,191,000 |
| Reconciled Depreciation | $11,193,000 | $17,305,000 | $12,004,000 | $9,583,000 |
| EBITDA (Bullshit earnings) | $-108,624,000 | $-120,702,000 | $142,490,000 | $-206,089,000 |
| EBIT | $-119,817,000 | $-138,007,000 | $130,486,000 | $-215,672,000 |
| Diluted Average Shares | $75,878,738 | $68,863,010 | $65,249,184 | $52,131,596 |
| Basic Average Shares | $75,846,681 | $68,863,010 | $65,194,775 | $51,553,869 |
| Diluted NI Availto Com Stockholders | $-122,555,000 | $-118,674,000 | $124,110,000 | $-240,377,000 |
| Tax Provision | $6,084,000 | $-568,000 | $10,893,000 | $-516,000 |
| Impairment Of Capital Assets | $17,287,000 | $0 | $0 | - |
| Gain On Sale Of Security | $776,000 | $-1,185,000 | $1,152,000 | $1,191,000 |
| Research And Development | $134,621,000 | $143,619,000 | $208,596,000 | $199,752,000 |
| Selling General And Administration | $61,500,000 | $70,400,000 | $73,400,000 | $42,600,000 |
| Other Gand A | $35,400,000 | $48,100,000 | $49,600,000 | $24,700,000 |
| Salaries And Wages | $26,100,000 | $22,300,000 | $23,800,000 | $17,900,000 |
| Otherunder Preferred Stock Dividend | - | - | $231,000 | $28,534,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $322,176,000 | $427,506,000 | $454,557,000 | $215,612,000 |
| Total Assets | $463,091,000 | $580,880,000 | $648,725,000 | $389,132,000 |
| Total Non Current Assets | $162,640,000 | $167,954,000 | $104,019,000 | $100,912,000 |
| Other Non Current Assets | $8,919,000 | $7,566,000 | - | - |
| Non Current Deferred Assets | $4,385,000 | $3,615,000 | $1,355,000 | $4,284,000 |
| Non Current Deferred Taxes Assets | $4,385,000 | $3,615,000 | $1,345,000 | $3,070,000 |
| Goodwill And Other Intangible Assets | $16,592,000 | $37,300,000 | $38,399,000 | $33,482,000 |
| Other Intangible Assets | $4,576,000 | $25,284,000 | $26,383,000 | $21,466,000 |
| Current Assets | $300,451,000 | $412,926,000 | $544,706,000 | $288,220,000 |
| Other Current Assets | $18,860,000 | $19,122,000 | $19,074,000 | $19,998,000 |
| Receivables | $55,815,000 | $19,477,000 | $33,400,000 | $15,614,000 |
| Accounts Receivable | $55,815,000 | $19,477,000 | $33,400,000 | $15,614,000 |
| Cash Cash Equivalents And Short Term Investments | $225,776,000 | $374,327,000 | $492,232,000 | $252,608,000 |
| Cash And Cash Equivalents | $66,103,000 | $157,557,000 | $400,912,000 | $201,867,000 |
| Non Current Prepaid Assets | - | $7,240,000 | $15,729,000 | $12,490,000 |
| Prepaid Assets | - | - | - | $19,998,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $18,506,000 | $26,722,000 | $28,113,000 | $32,333,000 |
| Long Term Debt And Capital Lease Obligation | $15,766,000 | $22,461,000 | $24,791,000 | $31,023,000 |
| Current Debt And Capital Lease Obligation | $2,740,000 | $4,261,000 | $3,322,000 | $1,310,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $124,323,000 | $116,074,000 | $155,769,000 | $140,038,000 |
| Total Non Current Liabilities Net Minority Interest | $36,029,000 | $60,311,000 | $60,144,000 | $68,185,000 |
| Other Non Current Liabilities | $895,000 | $1,609,000 | $2,977,000 | $2,648,000 |
| Non Current Deferred Liabilities | $19,368,000 | $36,241,000 | $32,376,000 | $34,514,000 |
| Non Current Deferred Taxes Liabilities | $4,761,000 | $3,300,000 | $1,788,000 | $1,573,000 |
| Current Liabilities | $88,294,000 | $55,763,000 | $95,625,000 | $71,853,000 |
| Other Current Liabilities | $1,264,000 | $2,530,000 | $1,642,000 | $7,754,000 |
| Current Deferred Liabilities | $25,588,000 | $3,699,000 | $2,353,000 | $0 |
| Payables And Accrued Expenses | $52,480,000 | $39,120,000 | $73,943,000 | $59,443,000 |
| Payables | $5,281,000 | $8,023,000 | $26,786,000 | $7,416,000 |
| Total Tax Payable | $1,378,000 | $1,811,000 | $17,084,000 | $0 |
| Income Tax Payable | $128,000 | $1,811,000 | $840,000 | $0 |
| Accounts Payable | $3,903,000 | $6,212,000 | $7,863,000 | $5,174,000 |
| Other Payable | - | $729,000 | $1,839,000 | $2,242,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $338,768,000 | $464,806,000 | $492,956,000 | $249,094,000 |
| Total Equity Gross Minority Interest | $338,768,000 | $464,806,000 | $492,956,000 | $249,094,000 |
| Stockholders Equity | $338,768,000 | $464,806,000 | $492,956,000 | $249,094,000 |
| Gains Losses Not Affecting Retained Earnings | $-6,952,000 | $-6,603,000 | $-6,659,000 | $-6,659,000 |
| Other Equity Adjustments | $-6,952,000 | $-6,603,000 | $-6,659,000 | $-6,659,000 |
| Retained Earnings | $-830,335,000 | $-677,437,000 | $-558,763,000 | $-683,104,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $68,964,319 | $70,115,997 | $63,059,501 | $46,633,935 |
| Share Issued | $68,964,319 | $70,115,997 | $63,059,501 | $46,633,935 |
| Tangible Book Value | $322,176,000 | $427,506,000 | $454,557,000 | $215,612,000 |
| Invested Capital | $338,768,000 | $464,806,000 | $492,956,000 | $249,094,000 |
| Working Capital | $212,157,000 | $357,163,000 | $449,081,000 | $216,367,000 |
| Capital Lease Obligations | $18,506,000 | $26,722,000 | $28,113,000 | $32,333,000 |
| Total Capitalization | $338,768,000 | $464,806,000 | $492,956,000 | $249,094,000 |
| Additional Paid In Capital | $152,249,000 | $142,274,000 | $151,614,000 | $197,710,000 |
| Capital Stock | $1,023,806,000 | $1,006,572,000 | $906,764,000 | $741,147,000 |
| Common Stock | $1,023,806,000 | $1,006,572,000 | $906,764,000 | $741,147,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $14,607,000 | $32,941,000 | $30,588,000 | $32,941,000 |
| Long Term Capital Lease Obligation | $15,766,000 | $22,461,000 | $24,791,000 | $31,023,000 |
| Current Deferred Revenue | $25,588,000 | $3,699,000 | $2,353,000 | $0 |
| Current Capital Lease Obligation | $2,740,000 | $4,261,000 | $3,322,000 | $1,310,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,222,000 | $6,153,000 | $14,365,000 | $3,346,000 |
| Current Accrued Expenses | $47,199,000 | $31,097,000 | $47,157,000 | $52,027,000 |
| Investments And Advances | $98,428,000 | $81,930,000 | $886,000 | $886,000 |
| Goodwill | $12,016,000 | $12,016,000 | $12,016,000 | $12,016,000 |
| Net PPE | $34,316,000 | $37,543,000 | $47,650,000 | $49,770,000 |
| Accumulated Depreciation | $-17,830,000 | $-20,656,000 | $-13,299,000 | $-14,061,000 |
| Gross PPE | $52,146,000 | $58,199,000 | $60,949,000 | $63,831,000 |
| Leases | $15,190,000 | $20,992,000 | $20,960,000 | $9,104,000 |
| Construction In Progress | $0 | $122,000 | $76,000 | $13,257,000 |
| Other Properties | $29,997,000 | $29,503,000 | $32,635,000 | $35,313,000 |
| Machinery Furniture Equipment | $6,959,000 | $7,582,000 | $7,278,000 | $6,157,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $159,673,000 | $216,770,000 | $91,320,000 | $50,741,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-113,110,000 | $-122,380,000 | $130,984,000 | $-205,736,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-110,044,000 | $-118,303,000 | $144,109,000 | $-192,451,000 |
| Cash Flow From Continuing Operating Activities | $-110,044,000 | $-118,303,000 | $144,109,000 | $-192,451,000 |
| Operating Gains Losses | $-1,481,000 | $-31,000 | $-1,956,000 | $-433,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-3,066,000 | $-4,077,000 | $-13,125,000 | $-13,285,000 |
| Investing Cash Flow | $38,756,000 | $-207,253,000 | $-53,849,000 | $144,596,000 |
| Cash Flow From Continuing Investing Activities | $38,756,000 | $-207,253,000 | $-53,849,000 | $144,596,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-30,051,000 | $0 | $0 | - |
| Issuance Of Capital Stock | $0 | $76,095,000 | $107,534,000 | $0 |
| Financing Cash Flow | $-20,452,000 | $81,847,000 | $108,582,000 | $8,011,000 |
| Cash Flow From Continuing Financing Activities | $-20,452,000 | $81,847,000 | $108,582,000 | $8,011,000 |
| Net Other Financing Charges | $-174,000 | $-53,000 | $-596,000 | $-470,000 |
| Net Common Stock Issuance | $-30,051,000 | $76,095,000 | $107,534,000 | $0 |
| Common Stock Issuance | $0 | $76,095,000 | $107,534,000 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-14,000 | $-21,000 | $-14,000 | $-17,000 |
| Income Tax Paid Supplemental Data | $3,179,000 | $165,000 | $10,000,000 | - |
| End Cash Position | $66,103,000 | $157,557,000 | $400,912,000 | $201,867,000 |
| Beginning Cash Position | $157,557,000 | $400,912,000 | $201,867,000 | $242,036,000 |
| Effect Of Exchange Rate Changes | $286,000 | $354,000 | $203,000 | $-325,000 |
| Changes In Cash | $-91,740,000 | $-243,709,000 | $198,842,000 | $-39,844,000 |
| Proceeds From Stock Option Exercised | $9,787,000 | $5,826,000 | $1,658,000 | $8,498,000 |
| Common Stock Payments | $-30,051,000 | $0 | $0 | - |
| Net Issuance Payments Of Debt | $-14,000 | $-21,000 | $-14,000 | $-17,000 |
| Net Long Term Debt Issuance | $-14,000 | $-21,000 | $-14,000 | $-17,000 |
| Long Term Debt Payments | $-14,000 | $-21,000 | $-14,000 | $-17,000 |
| Net Investment Purchase And Sale | $41,822,000 | $-203,176,000 | $-40,724,000 | $157,881,000 |
| Sale Of Investment | $325,565,000 | $350,073,000 | $72,281,000 | $192,962,000 |
| Purchase Of Investment | $-283,743,000 | $-553,249,000 | $-113,005,000 | $-35,081,000 |
| Net Intangibles Purchase And Sale | $-1,075,000 | $-1,603,000 | $-4,975,000 | $-881,000 |
| Purchase Of Intangibles | $-1,075,000 | $-1,603,000 | $-4,975,000 | $-881,000 |
| Net PPE Purchase And Sale | $-1,991,000 | $-2,474,000 | $-8,150,000 | $-12,404,000 |
| Purchase Of PPE | $-1,991,000 | $-2,474,000 | $-8,150,000 | $-12,404,000 |
| Change In Working Capital | $-30,953,000 | $-25,545,000 | $4,015,000 | $393,000 |
| Change In Other Working Capital | $3,555,000 | $3,699,000 | - | - |
| Change In Other Current Liabilities | $-8,313,000 | $-3,663,000 | $-3,736,000 | $-26,000 |
| Change In Payables And Accrued Expense | $12,653,000 | $-43,798,000 | $27,319,000 | $16,477,000 |
| Change In Payable | $12,653,000 | $-43,798,000 | $27,319,000 | $16,477,000 |
| Change In Account Payable | $14,335,000 | $-44,768,000 | $26,479,000 | $16,477,000 |
| Change In Tax Payable | $-1,682,000 | $970,000 | $840,000 | $0 |
| Change In Income Tax Payable | $-1,682,000 | $970,000 | $840,000 | $0 |
| Change In Prepaid Assets | $-2,489,000 | $4,295,000 | $-2,059,000 | $-15,792,000 |
| Change In Receivables | $-36,359,000 | $13,922,000 | $-17,509,000 | $-266,000 |
| Changes In Account Receivables | $-36,359,000 | $13,922,000 | $-17,509,000 | $-266,000 |
| Other Non Cash Items | $-1,878,000 | $630,000 | $-250,000 | $213,000 |
| Stock Based Compensation | $17,792,000 | $8,102,000 | $4,015,000 | $10,756,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $667,000 | $0 | $-167,000 |
| Asset Impairment Charge | $17,287,000 | $0 | $0 | $0 |
| Deferred Tax | $691,000 | $-757,000 | $1,940,000 | $-953,000 |
| Deferred Income Tax | $691,000 | $-757,000 | $1,940,000 | $-953,000 |
| Depreciation Amortization Depletion | $11,193,000 | $17,305,000 | $12,004,000 | $9,583,000 |
| Depreciation And Amortization | $11,193,000 | $17,305,000 | $12,004,000 | $9,583,000 |
| Amortization Cash Flow | $4,496,000 | $2,702,000 | $1,015,000 | $2,793,000 |
| Amortization Of Intangibles | $4,496,000 | $2,702,000 | $1,015,000 | $2,793,000 |
| Depreciation | $6,697,000 | $14,603,000 | $10,989,000 | $6,790,000 |
| Net Foreign Currency Exchange Gain Loss | $-1,481,000 | $-31,000 | $-1,956,000 | $-433,000 |
| Net Income From Continuing Operations | $-122,695,000 | $-118,674,000 | $124,341,000 | $-211,843,000 |